Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CXM +12.4%, RH +9.1%, CWCO +6.4%, VRNT +3.9%, USAP +2.3%
Other news:
- AKBA +17.9% (receives FDA approval of Vafseo Tablets)
- ERAS +14.1% (enters into a securities purchase agreement to sell 21,844,660 shares of common stock in an oversubscribed private placement at a price of $2.06 per share)
- HCM +7.7% (receives sNDA acceptance for Savolitinib in China for treatment-naïve or previously treated patients with locally advanced or metastatic MET Exon 14 NSCLC)
- ABOS +6.8% (files $200 mln mixed shelf securities offering)
- RILY +5.4% (has secured an extension under its existing credit agreement with Nomura Corporate Funding Americas)
- STOK +3.1% (prices upsized $125 million public offering)
- SNOW +3% (CEO bought 31542 shares worth ~$5 mln)
- ALDX +2.9% (announces the clinical development plan intended to enable resubmission of a New Drug Application of topical ocular 0.25% reproxalap)
- GDS +2.7% (discloses Series A Preferred Share Subscription Agreement)
- HITI +2.4% (closes acquisition of Canadian cannabis brand Queen of Bud)
- HA +1.4% (HA and ALK enter into timing agreement with DOJ relating to merger)
- SGMT +1.2% (completes Phase 1 hepatic impairment study with denifanstat)